BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 9000573)

  • 21. Determination of p53 mutations, EGFR overexpression, and loss of p16 expression in pediatric glioblastomas.
    Sure U; Rüedi D; Tachibana O; Yonekawa Y; Ohgaki H; Kleihues P; Hegi ME
    J Neuropathol Exp Neurol; 1997 Jul; 56(7):782-9. PubMed ID: 9210874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
    de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
    Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945.
    Fouladi M; Hunt DL; Pollack IF; Dueckers G; Burger PC; Becker LE; Yates AJ; Gilles FH; Davis RL; Boyett JM; Finlay JL
    Cancer; 2003 Sep; 98(6):1243-52. PubMed ID: 12973849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of p53 immunoreactivity and sequencing in patients with glioma.
    Kyritsis AP; Xu R; Bondy ML; Levin VA; Bruner JM
    Mol Carcinog; 1996 Jan; 15(1):1-4. PubMed ID: 8561860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Basic fibroblast growth factor expression as a predictor of prognosis in pediatric high-grade gliomas.
    Bredel M; Pollack IF; Campbell JW; Hamilton RL
    Clin Cancer Res; 1997 Nov; 3(11):2157-64. PubMed ID: 9815610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
    Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
    Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 status has no prognostic significance in glioblastomas treated with radiotherapy.
    Baxendine-Jones J; Campbell I; Ellison D
    Clin Neuropathol; 1997; 16(6):332-6. PubMed ID: 9401801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Near complete surgical resection predicts a favorable outcome in pediatric patients with nonbrainstem, malignant gliomas: results from a single center in the magnetic resonance imaging era.
    Bucci MK; Maity A; Janss AJ; Belasco JB; Fisher MJ; Tochner ZA; Rorke L; Sutton LN; Phillips PC; Shu HK
    Cancer; 2004 Aug; 101(4):817-24. PubMed ID: 15305415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
    Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
    J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas.
    Lima-Ramos V; Pacheco-Figueiredo L; Costa S; Pardal F; Silva A; Amorim J; Lopes JM; Reis RM
    Cancer Genet Cytogenet; 2008 Jan; 180(1):14-9. PubMed ID: 18068527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 mutation, EGFR gene amplification and loss of heterozygosity on chromosome 10, 17 p in human gliomas.
    Jin W; Xu X; Yang T; Hua Z
    Chin Med J (Engl); 2000 Jul; 113(7):662-6. PubMed ID: 11776043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort.
    Pollack IF; Hamilton RL; James CD; Finkelstein SD; Burnham J; Yates AJ; Holmes EJ; Zhou T; Finlay JL;
    J Neurosurg; 2006 Nov; 105(5 Suppl):418-24. PubMed ID: 17328268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.